Stanford University scientists discovered that ribosomes, the cellular machinery that builds proteins, increasingly collide and stall as organisms age [1, 2].
This discovery provides a potential biological explanation for why brains decline over time. By identifying the mechanism that creates faulty proteins, researchers may find new ways to prevent the aggregates associated with Alzheimer's disease [1, 2].
The research team conducted experiments using the turquoise killifish, known as Nothobranchius furzeri [1, 2]. This specific model allowed the scientists to observe how the protein-building process degrades over a lifespan. The study found that as the fish aged, the ribosomes began to experience "traffic jams" [1, 2].
When ribosomes collide, they fail to complete the production of proteins correctly. This process results in the creation of faulty proteins and the formation of aggregates, clumps of misfolded proteins that are a hallmark of neurodegenerative conditions [1, 2]. These aggregates are closely linked to memory loss and the pathology of Alzheimer's disease [1, 2].
The team aimed to uncover a hidden biological mechanism that explains the physical decline of the brain. By focusing on the ribosomal level, the researchers identified a specific failure in cellular machinery that precedes the visible symptoms of cognitive decline [1, 2].
While the study utilized fish models, the fundamental process of protein synthesis is similar across many species. The researchers said that these ribosomal stalls are a significant cause of aging and the subsequent loss of memory [1, 2].
“Ribosomes increasingly collide and stall with age, leading to faulty proteins.”
This research shifts the focus of Alzheimer's and aging studies from the proteins themselves to the machinery that creates them. By demonstrating that 'traffic jams' in the ribosome cause protein aggregation, the study suggests that therapeutic interventions targeting the efficiency of protein synthesis, rather than just clearing existing plaques, could be a viable path for treating neurodegenerative diseases.
